Catamaran Bio
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
451 D St Fl 5, Boston, Massachusetts, 02...Phone Number
(857) 758-5800Website
www.catamaranbio.comRevenue
$6.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Catamaran Bio
Based out of Cambridge, MA, Catamaran Bio is a biotechnology company with a focus on cell therapies to treat cancer.Explore more
Catamaran Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Catamaran Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Catamaran Bio
Earning: See what the market has to say on Catamaran Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Catamaran Bio has new funding data
Click to see if Catamaran Bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Catamaran Bio launches new products
Catamaran Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Catamaran Bio is spiking on competitors!
Check if Catamaran Bio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Catamaran Bio
Compare insights from companies similar to Catamaran Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Catamaran Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Catamaran Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Catamaran Bio.
Catamaran Bio financials insights
Gather financial insights about Catamaran Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$42M
Catamaran Bio Tech Stack
A closer look at the technologies used by Catamaran Bio
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
New Hire
Executive Move
Board of Directors
New Hire
Executive Move
Catamaran Bio News & Media
Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies
BOSTON & TORONTO--(BUSINESS WIRE)--Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio Inc., a contract development and manufacturing organization (CDMO) focused on cell and gene therapy, today announced their partnership to develop and manufacture Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors. “This collaboration will allow us to develop scalable processes for the rMaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapiesCatamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catamaran Bio, Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, today announced new data demonstrating preclinical efficacy of two CAR-NK cell therapies in solid and hematological cancers. The data are being presented in two posters at the Society for Immunotherapy in Cancer (SITC) 37th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022. “Collectively, these preclinical data sets demonstrate the poCatamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR‑NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf NK cell therapies to treat cancer, today announced that the company will present preclinical efficacy data for its allogeneic, cryopreserved CAR-NK cell therapies designed to treat solid tumors, engineered using Catamaran’s TAILWINDTM platform. The data demonstrate the promise of two of the company’s CAR-NK cell therapies, CAT-248 and CAT-179, for the treatment of solid tumors, and will be p
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Catamaran Bio
Sign Up For FreeTo access detailed company insights
Based out of Cambridge, MA, Catamaran Bio is a biotechnology company with a focus on cell therapies to treat cancer.... Read More
